Funder
National Cancer Institute
Canadian Cancer Society
GlaxoSmithKline
Novartis
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792 (cited 28 May 2021).
2. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724–734 (cited 28 May 2021). https://www.nejm.org/doi/full/
3. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791 (cited 28 May 2021). https://www.nejm.org/doi/full/
4. Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R et al (2022) Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 386(12):1143–1154 (cited 5 Aug 2022). https://www.nejm.org/doi/full/
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672 (cited 28 May 2021). https://pubmed.ncbi.nlm.nih.gov/16236737/